Acumen Pharmaceuticals, Inc.
General ticker "ABOS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $88.2M (TTM average)
Acumen Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 49.5%.
Estimated limits based on current volatility of 3.0%: low 2.65$, high 2.81$
Factors to consider:
- Total employees count: 52 (+30.0%) as of 2023
- Top business risk factors: Operational and conduct risks, Funding dependency, Liquidity and credit risks, Litigation risks, Regulatory and compliance
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.58$, 4.27$]
- 2026-12-31 to 2027-12-31 estimated range: [1.30$, 3.57$]
Financial Metrics affecting the ABOS estimates:
- Positive: with PPE of -1.1 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -90.20 <= 0.07
- Positive: 42.60 < Shareholder equity ratio, % of 57.34 <= 64.25
- Positive: Investing cash flow per share per price, % of 104.56 > -0.65
- Positive: Inventory ratio change, % of -100 <= -0.75
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Industry operating cash flow (median)
Short-term ABOS quotes
Long-term ABOS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $61.14MM | $114.02MM | $123.83MM |
| Operating Income | $-61.14MM | $-114.02MM | $-123.83MM |
| Non-Operating Income | $8.77MM | $11.69MM | $2.50MM |
| Interest Expense | $0.58MM | $4.07MM | $4.22MM |
| R&D Expense | $42.32MM | $93.80MM | $104.89MM |
| Income(Loss) | $-52.37MM | $-102.33MM | $-121.33MM |
| Profit(Loss)* | $-52.37MM | $-102.33MM | $-121.33MM |
| Stockholders Equity | $266.97MM | $181.82MM | $70.43MM |
| Inventory | $0.00MM | $0.16MM | $0.00MM |
| Assets | $310.12MM | $238.99MM | $122.83MM |
| Operating Cash Flow | $-43.06MM | $-86.22MM | $-115.54MM |
| Capital expenditure | $0.02MM | $0.02MM | $0.09MM |
| Investing Cash Flow | $-171.67MM | $48.03MM | $133.93MM |
| Financing Cash Flow | $151.75MM | $6.93MM | $-0.03MM |
| Earnings Per Share** | $-1.08 | $-1.71 | $-2.00 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.